Life Sciences & Biotechnology
Title : | Understanding the role of PARP16 in the development of cardiac lipotoxicity |
Area of research : | Life Sciences & Biotechnology |
Focus area : | Cell Biology |
Principal Investigator : | Dr. Ravi sundaresan Nagalingam, Indian Institute of science, Bangalore, Karnataka |
Timeline Start Year : | 2024 |
Timeline End Year : | 2027 |
Contact info : | rsundaresan@mcbl.iisc.ernet.in |
Details
Executive Summary : | Cardiovascular diseases (CVDs) are the leading cause of death worldwide, with a quarter of all deaths in India attributed to CVDs. Metabolic disorders like obesity, insulin resistance, and diabetes are characterized by dyslipidemia, which progresses to myocardial lipotoxicity and predisposes patients to heart failure. These syndromes have significant personal, social, and economic impacts, potentially affecting India's economic growth. Current therapeutic options treat symptoms, but insufficient understanding of the molecular players involved in heart failure's development and progression limits the development of novel therapeutics. Preliminary data shows a significant increase in PARP16 protein levels in the hearts of high fat diet-fed mice and db or db mice, which suffer from myocardial lipotoxicity. The proposed study aims to identify the role of PARP16 as a regulator of these pathways and investigate the molecular mechanisms by which it may be implicated in the development of cardiac lipotoxicity. The findings could provide novel insights into molecular players involved in cardiac lipotoxicity and identify key proteins that mediate cardiac metabolism, potentially serving as a potential therapeutic target for patients with metabolic comorbidities associated with heart failure. |
Co-PI: | Prof. sachin Kotak, Indian Institute of science, Bangalore, Karnataka |
Total Budget (INR): | 66,24,400 |
Organizations involved